Tanvex BioPharmaTPE:6541 +2.10%57 PB Ratio is 1.93 as of Jul. 05, 2026, which is 74% below its 10-year median of 7.45. GuruFocus rates TPE:6541 with a GF Score™ of 57/100 and a GF Value™ of NT$254.61 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 1,230 Biotechnology companies, Tanvex BioPharma ranks better than 65.12% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-05), Tanvex BioPharma's share price is NT$41.40. Tanvex BioPharma's Book Value per Share for the quarter that ended in Dec. 2025 was NT$21.50. Hence, Tanvex BioPharma's PB Ratio of today is 1.93.
Good Sign:
Tanvex BioPharma Inc stock PB Ratio (=1.93) is close to 10-year low of 1.78.
The historical rank and industry rank for Tanvex BioPharma's PB Ratio or its related term are showing as below:
TPE:6541'
s PB Ratio Range Over the Past 10 Years
Min: 1.78 Med: 7.45 Max: 16.47
Current: 1.93
During the past 13 years, Tanvex BioPharma's highest PB Ratio was 16.47. The lowest was 1.78. And the median was 7.45.
TPE:6541's PB Ratio is ranked better than 65.12% of 1230
companies
in the Biotechnology industry
Industry Median: 2.98
vs TPE:6541: 1.93
During the past 12 months, Tanvex BioPharma's average Book Value Per Share Growth Rate was 298.10% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 23.60% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -14.60% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was -15.60% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Tanvex BioPharma was 100.50% per year. The lowest was -38.20% per year. And the median was -17.35% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Tanvex BioPharma PB Ratio Related Terms
Tanvex BioPharma PB Ratio Historical Data
* Premium members only.
The historical data trend for Tanvex BioPharma's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Tanvex BioPharma's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tanvex BioPharma PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tanvex BioPharma's PB Ratio distribution charts can be found below:
* The bar in red indicates where Tanvex BioPharma's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Tanvex BioPharma (TPE:6541) has a PB Ratio of 1.93 as of Jul. 05, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Tanvex BioPharma and its competitors. This is 74% below median its historical median of 7.45. Over the past decade, Tanvex BioPharma's PB Ratio has ranged from 1.78 to 16.47. According to the industry distribution chart, Tanvex BioPharma ranks #429 out of 1230 companies in the Biotechnology industry, placing it in the top 34.9%.
Is Tanvex BioPharma's PB Ratio too high?
Tanvex BioPharma's current PB Ratio of 1.93 is 74% below median its 10-year median of 7.45. Over the past 10 years, this metric has ranged from a low of 1.78 to a high of 16.47. The Biotechnology industry median PB Ratio is 2.98. Tanvex BioPharma's value of 1.93 is 35.2% below this industry median. Based on the distribution chart, Tanvex BioPharma ranks #429 out of 1230 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Tanvex BioPharma has a GF Score™ of 57/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Tanvex BioPharma's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Tanvex BioPharma ranks #429 out of 1230 companies for PB Ratio. This puts Tanvex BioPharma in the upper half of its industry. The industry median PB Ratio is 2.98. Tanvex BioPharma's value of 1.93 is 35.2% below this benchmark. Historically, Tanvex BioPharma's own PB Ratio has ranged from 1.78 to 16.47 over the past decade. While the company's 10-year median is 7.45 vs. the industry median of 2.98, Tanvex BioPharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.98, based on 1,230 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tanvex BioPharma's current PB Ratio of 1.93 is 35.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Tanvex BioPharma and its competitors. For the Biotechnology industry, the median PB Ratio is 2.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tanvex BioPharma's current PB Ratio is 1.93, which is 74% below median its own 10-year median of 7.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tanvex BioPharma stock overvalued right now?
Based on GuruFocus' analysis, Tanvex BioPharma (TPE:6541) is currently considered Possible Value Trap. The stock's GF Value™ is NT$254.61, compared to a current price of NT$41.40 — trading 83.7% below its estimated fair value. The current PB Ratio is 1.93, which is 74% below median its 10-year median of 7.45 and 35.2% below the Biotechnology industry median of 2.98. Tanvex BioPharma's overall GF Score™ is 57/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Tanvex BioPharma (TPE:6541), the current PB Ratio is 1.93 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tanvex BioPharma (TPE:6541) Overvalued in 2026?
Based on GuruFocus' analysis, Tanvex BioPharma stock appears to be undervalued.
The current stock price of NT$41.40 is trading 83.7% below its estimated GF Value™ of NT$254.61.
GuruFocus considers Tanvex BioPharma to be Possible Value Trap.
Key valuation signals for TPE:6541:
PB Ratio: 1.93 (74% below median its 10-year median of 7.45)
GF Value™: NT$254.61 vs. price of NT$41.40 (83.7% below fair value)
Industry Position: 35.2% below the Biotechnology median (#429 of 1230)
No single metric tells the full story. See the TPE:6541 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tanvex BioPharma Inc is a biopharmaceutical company. It is engaged in the research, development, manufacture, and sale of biosimilar products and contract development and manufacturing of biological medicine. The company's products are used to cure diseases such as Neutropenia, Breast Cancer, Metastatic Colorectal Cancer, and others. Geographically, the company operates in Asia, America, Europe, and Australia. The company generates a majority of its revenue from the USA.
57GF Score
Get the complete analysis for TPE:6541
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:6541 has been successfully added to your 
